Section Arrow
Quote
INDP.NASDAQ
- Indaptus Therapeutics Inc
Quotes are at least 15-min delayed:2026/04/15 09:41 EDT
Regular Hours
Last
 2.2201
-0.1099 (-4.72%)
Day High 
2.27 
Prev. Close
2.33 
1-M High
2.6 
Volume 
4.98K 
Bid
2.22
Ask
2.42
Day Low
2.2201 
Open
2.27 
1-M Low
1.51 
Market Cap 
5.22M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.84 
20-SMA 1.81 
50-SMA 1.84 
52-W High 19.9136 
52-W Low 1.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-21.58/-4.42
Enterprise Value
5.22M
Balance Sheet
Book Value Per Share
1.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.8799+0.5651+179.51%-- 
LIMNLiminatus Pharma Inc0.196+0.0162+9.01%-- 
ALLOAllogene Therapeutics1.885-0.395-17.32%-- 
LNAILunai Bioworks Inc.0.2984-0.0404-11.92%-- 
RVMDRevolution Medicines149.035+2.025+1.38%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technologyis composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.